Genetic test flags prostate cancer patients at highest death risk

A new genetic test called Decipher can identify prostate cancer patients at higher risk of death, enabling more personalised treatment decisions. Developed by University College London scientists, it analyses tumour genes to predict cancer aggressiveness and spread likelihood. The test helps doctors minimise side effects by sparing low-risk men intensive treatment while prioritising high-risk patients for stronger therapies. Findings from over 6,000 men will be presented at the European Society for Medical Oncology Congress 2026 in Madrid. The research stems from the Stampede trial, which showed the drug abiraterone halves death risk in high-risk cases. The NHS widened access to abiraterone in January, potentially saving 3,000 lives annually.